Quantum SI

What Quantum SI does

Quantum-Si Incorporated (NASDAQ: QSI) is a publicly traded life sciences tools company that develops semiconductor-based single-molecule protein sequencing platforms for academic research, biopharmaceutical, and clinical research customers. Founded in 2013 by Jonathan Rothberg (inventor of Ion Torrent semiconductor sequencing) and headquartered in Branford, Connecticut, the company commercialized the first benchtop next-generation protein sequencer — the Platinum in 2023 — followed by the Platinum Pro in March 2025, both available in 30+ countries through direct sales and channel partners including Avantor. Its proprietary technology uses CMOS semiconductor chips with fluorescently labeled N-terminal amino acid (NAA) recognizers and aminopeptidases to generate kinetic signatures that uniquely identify peptides at single-molecule, single-amino-acid resolution, distinguishing isobaric variations such as isoleucine and leucine that mass spectrometry cannot resolve.

The revenue model is a classic razor-and-blade structure: instrument sales (Platinum, Platinum Pro, and the upcoming Proteus platform at a $425,000 list price planned for end-of-2026 commercial launch) plus recurring consumables including Sequencing Kits V3/V4, Library Prep Kits, Barcoding Kits (24-plex), chips, recognizers, and aminopeptidases, supplemented by service contracts. Reported revenue was $2.4 million in FY2025 with Q1 2026 revenue of $258,000 and FY2026 guidance of approximately $1 million as the company deprioritizes current product sales to prepare the market for Proteus. The 2026 product roadmap adds 100x sensitivity improvements in library prep (200ng input vs 8-40µg), 85% more sequenceable peptides via the V4 sequencing kit, all-20-amino-acid detection on Proteus, and ecosystem partnerships (NVIDIA for accelerated computing, SkyWater Technology for chip manufacturing, Cell Signaling Technology for PTM kinetic signature databases, plus academic collaborators at Stanford, Northwestern, and UVA). Quantum-Si went public via SPAC merger in February 2021 at approximately $1.46 billion valuation and has since raised an additional $50 million via direct offering in July 2025, holding $190.4 million in cash at Q1 2026 to fund operations into Q2 2028 against a $101.3 million FY2025 net loss.

Name

Quantum SI

Legal name

Quantum-Si Incorporated

Website

https://quantum-si.com

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

101–250 employees

Short description

Quantum-Si (NASDAQ: QSI) develops semiconductor-based single-molecule protein sequencing platforms (Platinum, Platinum Pro, and upcoming Proteus) sold to academic, biopharma, and clinical research customers through a global direct-and-channel sales network spanning 30+ countries.

Ownership category

akta.pro rank

Product category

Proteomics Instruments and Reagents

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

akta.pro secondary industry

Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)

Keywords

• Single-molecule protein sequencing
• Benchtop proteomics instruments
• Kinetic signature detection
• Protein barcoding consumables
• Semiconductor NGS chips

Headquarters

HQ city

Guilford

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Instrument Sales: Revenue from sales of Platinum and Platinum Pro benchtop protein sequencing instruments. Proteus platform priced at $425,000 list price for commercial launch end of 2026.
2. Consumables: Recurring revenue from sequencing kits (V4 Sequencing Kit, V3 Library Prep Kit), chips, recognizers, and aminopeptidases. Volume expected to increase 25% as installed base matures.
3. Service and Support: Service revenue from installed base support and maintenance contracts.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

Quantum-Si develops and sells semiconductor-based benchtop single-molecule protein sequencing instruments (Platinum, Platinum Pro) and consumables (Sequencing Kits, Library Prep Kits, Barcoding Kits), supported by ProteoVue bioinformatics software. The NGPS platform reads kinetic signatures on CMOS chips to identify proteins, variants, and post-translational modifications at single-amino-acid resolution for academic, clinical, and biopharma researchers.

Product overview

Quantum-Si offers an integrated single-molecule proteomics platform centered on its Platinum and Platinum Pro benchtop protein sequencers, consumables (Sequencing Kits V3/V4, Library Prep Kits, Barcoding Kits), and Platinum Analysis Software. The flagship Platinum Pro delivers next-generation protein sequencing (NGPS) with single-molecule, single-amino-acid resolution using proprietary kinetic signature detection. The company is developing the Proteus platform (launch expected end of 2026) as the next-generation successor with expanded amino acid detection and increased throughput. The ecosystem includes the Tech Access Program for custom applications and ProteoVue bioinformatics for protein variant analysis. By integrating biology, chemistry, artificial intelligence, and semiconductor technology, Quantum-Si provides researchers with accessible benchtop protein sequencing for applications including protein identification, variant detection, PTM analysis, antibody characterization, and multiplexed protein barcoding.

Differentiator

Problem solved

Functional benefit

Brands

• Platinum Pro: Advanced benchtop next-generation protein sequencer with single-molecule precision and real-time kinetic insights
• Platinum
• Proteus
• KinetIQ Array
• ProteoVue
• Next-Gen Protein Sequencing (NGPS)
• Ultrasensitive Protein Detection (USPD)

Products and services

• Platinum Pro Advanced benchtop next-generation protein sequencer (NGPS) delivering single-molecule protein sequencing with real-time kinetic insights, automated data analysis, and a customizable user experience for variant detection and protein identification. Sold to academic researchers, clinical research labs, and biopharmaceutical scientists.
• Platinum First-generation end-to-end benchtop protein sequencer offering simple workflow with single-molecule amino acid resolution for accurate detection of protein variants and modifications. Sold to academic and biotech researchers.
• Sequencing Kit V4 Protein sequencing consumable kit with expanded proteome coverage, improved recognition of glycine and methionine, enhanced alanine and serine recognition, and ability to sequence through proline-rich regions common in antibodies and membrane proteins. Provides 85% increase in sequenceable peptides compared to previous version. Used by Platinum and Platinum Pro instrument customers.
• Library Prep Kit V3 High-sensitivity library preparation consumable kit requiring 200ng or less of total protein input, enabling detection of proteins with as little as 1-2ng input. Supports low-abundance detection and resolves immunoprecipitated protein mixtures with precision. Used by Platinum and Platinum Pro instrument customers.
• Barcoding Kit

Quantifiable outcome

• Proteus platform detects 17 amino acids (April 2026), targeting all 20 amino acids by year-end 2026
• +4 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

13 partnerships are on record, tiered core, major and minor.

• Cell Signaling TechnologycoreStrategic or Co-development Partner · 10 June 2026Partnership to advance post-translational modification analysis on Quantum-Si's Proteus single-molecule protein sequencing platform. Collaboration will integrate CST's PTM detection expertise and generate datasets to build and refine Quantum-Si's kinetic signature database for site-resolved protein detection. Second phase will benchmark Proteus results against orthogonal mass spectrometry data.
• Broad InstitutecoreStrategic or Co-development PartnerPlatinum Pro instrument placement to support scientific innovation in oncology, therapeutics, and biomedical research. Expands access to proteomics technology within Greater Boston life science ecosystem enabling regional researchers to collaborate on advanced applications.
• NVIDIAcoreTechnology or IntegrationCollaboration to develop acceleration platform and advance core technologies. Quantum-Si's platform for proteomics and multiomics utilizing NVIDIA technology for accelerated computing and AI.
• SkyWater TechnologycoreTechnology or IntegrationExpanded collaboration to develop new chip production process critical for Proteus platform. Semiconductor manufacturing partnership for next-generation proteomics platform.
• Planet InnovationmajorStrategic or Co-development PartnerPartnership for Proteus instrument development, combining expertise in instrument design and commercialization.
• IDEX Health & SciencemajorTechnology or IntegrationPartnership on optics module for Proteus instrument, providing specialized optical components.
• Liberate BiocoreStrategic or Co-development PartnerLiberate Bio integrating Quantum-Si's NGPS platform to enhance gene therapy development. Uses protein barcoding for high-throughput in vivo screening of lipid nanoparticles in non-human primates.
• AvantormajorChannel Partner/ Reseller/ DistributorDistribution agreement for Quantum-Si's Next-Generation Protein Sequencing technology in select markets.
• DNAnexusminorGTM or Marketing PartnerJoint webinar on proteomics data integration and standardization, featuring experts from DNAnexus, Olink, and Northwestern University.
• Oxford Expression TechnologiesminorStrategic or Co-development PartnerService provider expanding offering with Platinum-powered protein sequencing for customer access.
• Stanford UniversitycoreStrategic or Co-development PartnerAcademic collaboration resulting in peer-reviewed publication in Analytical Chemistry demonstrating semiconductor chip-based single-molecule protein sequencing for hemoglobin variant identification from blood samples.
• Northwestern UniversitycoreStrategic or Co-development PartnerResearch collaboration with Neil Kelleher's lab demonstrating complementarity of NGPS with individual ion mass spectrometry for IL-6 proteoforms. Published in Analytical and Bioanalytical Chemistry.
• University of VirginiacoreStrategic or Co-development PartnerCollaboration with Dr. Gloria Sheynkman on tropomyosin proteoforms research. First published manuscript by international researchers validating Quantum-Si technology for mechanistic biology research.

Scale indicators17 records

Recent moves9 records

Expansion highlights6 records

Emerging players

• Nautilus Biotechnology: Nautilus Biotechnology is an emerging single-molecule protein analysis company developing its own proteomics platform targeting similar applications in protein identification and variant detection. Closely comparable emerging competitor in the single-molecule protein analysis space.
• 908 Devices: 908 Devices (NASDAQ: MASS) develops mass spectrometry and analytical devices for life science and applied markets. Comparable as a smaller-scale analytical instrument developer targeting specialized proteomics and biomarker applications.
• Standard BioTools: Standard BioTools (NASDAQ: LAB) (formerly Fluidigm) provides analytical life science instruments including mass cytometry and proteomics tools. Comparable as a smaller-scale analytical instrument company serving proteomics and biomarker research markets.

Others

• Pacific Biosciences: Pacific Biosciences (NASDAQ: PACB) is a DNA sequencing platform developer. While focused on genomics rather than proteomics, comparable as a single-molecule analytical sequencing platform and shares technical lineage through common Ion Torrent DNA sequencing alumni (including Quantum-Si's CTO Todd Rearick).

Direct peers

• Olink Holding: Olink (NASDAQ: OLK) provides protein biomarker discovery platforms based on proximity extension assay technology. Directly comparable as a proteomics tools provider serving biopharma and academic researchers for biomarker discovery and drug development workflows.
• Seer: Seer (NASDAQ: SEER) is a direct competitor developing a commercial proteomics platform (Proteograph) for unbiased, deep proteomic analysis. Both companies are pioneering next-generation proteomics tools targeting academic and biopharma researchers transitioning from genomics-era workflows.
• SomaLogic: SomaLogic operates the SomaScan platform for high-throughput proteomic analysis using aptamer-based technology. Competes with Quantum-Si in the proteomics tools market targeting biomarker discovery, drug development, and clinical research customers.

Broad incumbents

• Waters Corporation: Waters (NYSE: WAT) is a broad analytical instrument manufacturer with significant mass spectrometry and chromatography presence in proteomics. Competes for proteomics instrument budgets across academic and biopharma customers.
• Thermo Fisher Scientific: Thermo Fisher Scientific (NYSE: TMO) is the dominant incumbent in mass spectrometry-based proteomics through its Orbitrap platform. The primary incumbent Quantum-Si's benchtop protein sequencing must displace in academic and biopharma labs.
• Bruker Corporation: Bruker (NASDAQ: BRKR) is a major mass spectrometry and proteomics instrument provider (timsTOF, MALDI-TOF) competing for the same proteomics research budgets. Strong incumbent in proteomics workflows with established customer relationships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/quantum_si
• YouTubeyoutube.com/channel/UCMwCU-1Qw093XKXcPI9yc4Q
• Facebookfacebook.com/Quantum-Si-102321301574765
• LinkedInlinkedin.com/company/quantum-si
• Instagraminstagram.com/quantum.si

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quantum SI